Investor Presentaiton slide image

Investor Presentaiton

Novo Nordisk Annual Report 2023 General terms and conditions of 2020-2023 programmes¹ Introducing Novo Nordisk Strategic Aspirations Risks Management Consolidated statements Additional information. Employees' Preliminary number of shares to be allocated 2 (million) Fair value per restricted stock unit at grant date (DKK) Performance and vesting period Allocation date Amortisation period 100 year anniversary programme 2023 2023 Management Board 2022 Management group below Management Board Individual employees 2021 2020 2023 2022 2021 2020 2023 2022 2021 3.0 0.6 0.7 1.0 0.9 3.1 3.3 3.0 2.4 0.3 0.8 0.3 446 2023 to 2026 Aug 2026 3.5 years 456 320 2022 to 2024 2021 to 2023 2020 to 2023 Feb 2025 Feb 2024 Feb 2024 3 years 3 years 4 years 212 206 456 2023 to 2025 Feb 2026 3 years 320 212 2022 to 2024 2021 to 2023 2020 to 2023 Feb 2025 Feb 2024 Feb 2024 3 years 4 years 206 3 years 544 2023 to 2026 2026 3 years 371 2022 to 2025 2021 to 2024 2025 269 2024 3 years 3 years 2023 to 2025 Feb 2026 3 years 1. As of 13 September 2023, the trading unit of the Novo Nordisk B shares listed on NASDAQ Copenhagen and ADRs listed on the New York Stock Exchange (NYSE) was changed from DKK 0.20 to DKK 0.10. Comparative figures have been restated to reflect the change in trading unit from DKK 0.20 to DKK 0.10. 2. The number of shares to be allocated under the LTIPS to Management Board and management group below Management Board, respectively, may potentially be reduced or increased depending on whether Novo Nordisk's performance during the three-year performance period is higher or lower compared to targets determined by the Board. The maximum number is capped. 77
View entire presentation